Home
Contact
Careers
Terms and Conditions
Privacy Policy
About Arcturus
RNA Medicines
Technologies
Pipeline
Patients and Family
Business Development
Publications
Investor Relations

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

August 18, 2022

Home
Contact
Careers
Terms and Conditions
Privacy Policy
© 2023 Arcturus Therapeutics, Inc.